Fig. 5From: Clinical and prognostic features of patients with detailed RAS/BRAF-mutant colorectal cancer in JapanProgression-free survival (PFS) of patients treated with doublet therapy with anti-VEGF agents. Analysis of PFS of hazard ratio based on RAS mutation status in patients with colorectal cancer treated with doublet therapy with anti-VEGF agents using Cox regression analysis (N = 43). P-value: Log-rank analysisBack to article page